HER2-overexpressing breast cancer: Time for the cure with less chemotherapy?

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 547-558

  Loi, Sherene ^a,b   De Azambuja, Evandro ^c   Pugliano, Lina ^b,c   Sotiriou, Christos ^a   Piccart, Martine J ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b Breast International Group (BIG) Headquarters   (Belgium)

^c BrEAST Data Center   (Belgium)

Author keywords

breast cancer; human epidermal growth factor 2 (HER2); neoadjuvant

Indexed keywords

ALVESPIMYCIN; ANTHRACYCLINE; BIOLOGICAL MARKER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; LAPATINIB; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; TANESPIMYCIN; TRASTUZUMAB;

ADAPTIVE IMMUNITY; ADJUVANT CHEMOTHERAPY; ALLERGIC REACTION; ANEMIA; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER REGRESSION; DIARRHEA; DRUG INDUCED HEADACHE; DYSPNEA; FATIGUE; HEARING IMPAIRMENT; HUMAN; NAIL DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; STOMATITIS; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 80054103145     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834bd4c9     Document Type: Review

References (64)

1. Negro A, Brar BK, Lee KF. Essential roles of HER2/ERBB2 in cardiac development and function. Recent Prog Horm Res 2004; 59:1-12. (Pubitemid 41327144)
2. Crone SA, Zhao YY, Fan L, et al. ERBB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8:459-465. (Pubitemid 34546747)
3. Yarden Y, Sliwkowski MX. Untangling the ERBB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137. (Pubitemid 33674041)
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182. (Pubitemid 17231334)
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244:707-712. (Pubitemid 19147683)
6. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36. (Pubitemid 46039831)
7. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
8. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-1281.
9. Von Minckwitz A, Kaufmann M, Keummel S, et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol 2011; 29 Suppl:abstract 1028.
10. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24:2019-2027. (Pubitemid 46622110)
11. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377-384.
12. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium [abstract S3-3]; 2010; San Antonio, Texas; 2010.
13. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). San Antonio Breast Cancer Symposium; 2010; San Antonio, Texas; 2010.
14. Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. Ann Oncol 2009; 20:1026-1031.
15. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743. (Pubitemid 46021510)
16. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ERBB signaling from the structure of the ERBB2-pertuzumab complex. Cancer Cell 2004; 5:317-328. (Pubitemid 38482068)
17. Fendly BM, Winget M, Hudziak RM, et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50:1550-1558. (Pubitemid 20090470)
18. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-1144.
19. Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008; 14:2710-2716.
20. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-145. (Pubitemid 350003059)
21. Loi S, Symmans WF, Bartlett JM, et al. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol 2011. [Epub ahead of print]
22. Chang JC, Mayer IA, Forero-Torres A, et al. TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol 2011; 29 Suppl:abstract 505.
23. TomaselloG, deAzambujaE, DinhP, et al. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008; 8:1883-1890.
24. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13:228-233. (Pubitemid 46121873)
25. Guarneri V, Frassoldati A, Bottini A, et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). J Clin Oncol 2011; 29 Suppl:abstract 507.
26. Untch M, Loibl S, Bischoff J, et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). San Antonio Breast Cancer Symposium; 2010; San Antonio, Texas; 2010.
27. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011; 29:1578-1586.
28. Press MF, Sauter G, Buyse M, et al. Alteration of topoisomerase II alpha gene in human breast cancer: association with responsiveness to anthracyclinebased chemotherapy. 2011; 29:859-867.
29. Alexe G, Dalgin GS, Scanfeld D, et al. High expression of lymphocyteassociated genes in node-negative HER2\+ breast cancers correlates with lower recurrence rates. Cancer Res 2007; 67:10669-10676. (Pubitemid 350145892)
30. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14:5158-5165.
31. Loi S, Salgado R, Piette F, et al. Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N\+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). J Clin Oncol 2011; 29 Suppl:abstract 556.
32. Bozovic-Spasojevic I, Azim HA Jr, Paesmans M, et al. Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe? Lancet Oncol 2011; 12:209-211.
33. Rimawi MF, Wiechmann LS, Wang YC, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 2011; 17:1351-1361.
34. Xia W, Bacus S, Husain I, et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther 2007; 9:292-299.
35. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874. (Pubitemid 32878711)
36. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-8423. (Pubitemid 36842560)
37. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100:10393-10398. (Pubitemid 37071889)
38. Loi S, Haibe-Kains B, Brown DN, et al. Correlation of molecular and clinically distinct phenotypes in H'2-overexpressing breast cancer (HER2\+ BC) with estrogen receptor status (ER) status: implications for anti-HER2 therapy. J Clin Oncol 2010; 28:15s. (Suppl; abstract 522).
39. Birnbaum D, Sircoulomb F, Imbert J. A reason why the ERBB2 gene is amplified and not mutated in breast cancer. Cancer Cell Int 2009; 9:5.
40. Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 Oncogene. Cell 2007; 129:1275-1286. (Pubitemid 46970708)
41. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456:663-666.
42. Hua G, Zhu B, Rosa F, et al. A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells. Mol Cancer Res 2009; 7:402-414.
43. Frasor J, Danes JM, Komm B, et al. Profiling of estrogen up-and downregulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144:4562-4574. (Pubitemid 37204856)
44. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-643.
45. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538-5546.
46. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27:5529-5537.
47. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-446. (Pubitemid 30208162)
48. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-170.
49. Stagg J, Loi S, Divisekera U, et al. Anti-ERBB2 mAb-therapy requires type I and II interferons and synergizes with anti-PD1 or anti-CD137 mAb-therapy. Proc Natl Acad Sci USA 2011; 108:7142-7147.
50. Dang C, Lin N, Moy B, et al. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neuoverexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 2010; 28:2982-2988.
51. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008; 26:3317-3323.
52. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ERBB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124-1130.
53. Swaby RBK, Jiang Z, Sun Y, et al. Neratinib in combinatin with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol 2009; 27(15 Suppl):abstract 1004.
54. DierasVHN, Albain K, Burris H, et al. A phase Ib/II trial of trastuzumab-DM1with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Cancer Res 2010; 70:1.
55. Miller KGL, Andre F, Dieras V, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2 positive, locally advanced or metastatic breast cancer who were previously treated with Trastuzumab. J Clin Oncol 2010; 28(15 Suppl).
56. Modi S, Stopeck AT, Linden HM, et al. HSP90 inhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17:5132-5139.
57. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25:5410-5417. (Pubitemid 350232217)
58. Modi SMK, Rosen LS, Schneider B, et al. Alvespimycin (KOS-1022) and trastuzumab (T): activity in HEr2\+ metastatic breast cancer (MBC). J Clin Oncol 2007; 2007 ASCO Breast Cancer Symposium:abstract 165.
59. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28:5110-5115.
60. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-1004.
61. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-440.
62. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-3074.
63. Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2010; 19:58-71.
64. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508. (Pubitemid 43259931)